Which cancer types is tisotumab vedotin-tftv suitable for?

Vedotin - Tisotumab vedotin-tftv is a prescription drug used to treat adults with cervical cancer that has returned or has spread to other parts of the body and who have received chemotherapy that didn't work or is no longer effective. Vietin-tisotumab was approved by the U.S. Food and Drug Administration (FDA) based on a clinical study that measured how many patients had a tumor response and how long that response lasted. Continued approval is dependent on the results of ongoing studies to confirm the benefits of vitin-tisotumab.

Cervical cancer originates in the cell-lining tissue of the cervix, located at the lower, narrow end of the uterus, and is primarily due to infection with the human papillomavirus. The disease typically develops slowly over time, withsigns and symptoms including vaginal bleeding, abnormal vaginal discharge, pelvic pain, and dyspareunia. Vitin-Tisotuzumab works as a tissue factor (TF)-directed ADC, a human IgG 1-κ antibody that targets the cell surface TF protein, which is the major initiator of the extrinsic coagulation cascade and TF plays a role in tumor signaling and angiogenesis. The antibody is linked via a protease-cleavable vc (valine-citrulline) linker to the small molecule monomethyl auristatin E (MMAE), a microtubule-disrupting agent, to form an ADC.

Vitin-TisotumabThe original drug has not yet been marketed in China, so it cannot be included in medical insurance. The original drugs marketed overseas are very expensive. The price of each box of 40 mg/vial may be around RMB 90,000 (the price may fluctuate due to the exchange rate). Currently, there is no generic version of Vitin-Tisotuzumab on the market. For more drug information and specific prices, please consult the medical consultant of the drug.